

Applicants : David M. Stern, et al.
U.S. Serial No. : 09/872,185
Filed : June 1, 2001
Page 2

Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the subject application:

1. (Withdrawn) A method for treating inflammation in a subject which comprises administering to the subject soluble receptor for advanced glycation endproduct (sRAGE) (SEQ. ID. NO:1) in an amount effective to treat inflammation in the subject.
2. (Withdrawn) A method for treating inflammation in a subject which comprises administering to the subject a polypeptide consisting essentially of the V-domain (SEQ. ID. NO:2) of receptor for advanced glycation endproduct (RAGE) in an amount effective to treat inflammation in the subject.
3. (Currently Amended) A method for treating inflammation in a subject which comprises administering to the subject an agent selected from the group consisting of soluble receptor for advanced glycation endproduct (sRAGE) or anti-RAGE antibody or anti-EN-RAGE F(ab')₂ fragment in an amount which inhibits the interaction between receptor for advanced glycation endproduct (RAGE) and ~~either ACE or~~ EN-RAGE, thereby treating inflammation in the subject.
- 4-6. (Canceled)
7. (Previously Presented) The method of claim 3 wherein the subject is a mammal.

Applicants : David M. Stern, et al.
U.S. Serial No. : 09/872,185
Filed : June 1, 2001
Page 3

8. (Original) The method of claim 7, wherein the mammal is a human.
9. (Previously Presented) The method of claim 3, wherein the administration comprises intralesional, intraperitoneal, intramuscular or intravenous injection; infusion; liposome-mediated delivery; topical, nasal, oral, anal, ocular or otic delivery.
10. (Original) The method of claim 3, wherein the agent is administered daily.
11. (Previously Presented) The method of claim 3, wherein the amount comprises a dose of from about 200 ng/day/kg body weight to about 200,000 ng/day/kg body weight.
12. (Previously Presented) The method of claim 3, wherein the inflammation is associated with a wound in the subject.
13. (Previously Presented) The method of claim 3, wherein the inflammation is associated with periodontal disease in the subject.
14. (Withdrawn) The method of any one of claims 1 to 2, wherein the inflammation is associated with an autoimmune disease in the subject.
15. (Withdrawn) The method of claim 14, wherein the autoimmune disease is multiple sclerosis or autoimmune encephalitis.

Applicants : David M. Stern, et al.
U.S. Serial No. : 09/872,185
Filed : June 1, 2001
Page 4

16. (Previously Presented) The method of claim 3, wherein the inflammation is associated with delayed-type hypersensitivity of a subject.
17. (Previously Presented) The method of claim 3, wherein the inflammation is associated with arthritis in a subject.
18. (Original) The method of claim 17, wherein the arthritis comprises collagen-induced arthritis, rheumatoid arthritis, psoriatic arthritis, osteoarthritis, arthritis due to Behchet's Syndrome, arthritis due to Sjogren's Syndrome, or arthritis induced by lupus.
- 19-25. (Canceled)